We are live on
!
Find out more
HSA
Hussman Strategic Advisors Portfolio holdings
AUM
$434M
1-Year Est. Return
19.64%
This Fund
S&P 500
1 Year Est. Return
+19.64%
AUM
$434M
AUM Growth
-$28.5M
(-6.2%)
Holding
334
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 | +$4.08M | |
| 2 | +$3.96M | |
| 3 | +$3.69M | |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$3.57M |
| 5 |
Globus Medical
GMED
|
+$3.57M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 | +$5.08M | |
| 2 | +$3.99M | |
| 3 | +$3.84M | |
| 4 |
Qualys
QLYS
|
+$3.69M |
| 5 |
Progyny
PGNY
|
+$3.57M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.08% |
| 2 | Technology | 17.18% |
| 3 | Consumer Discretionary | 15.3% |
| 4 | Financials | 9.77% |
| 5 | Consumer Staples | 9.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PepsiCo
PEP
$192B
| $5.12M | 1.18% |
37,800
+27,300
|
|
||
2
Ubiquiti
UI
$34.8B
| $5.05M | 1.16% |
9,450
+5,250
|
|
||
3
Incyte
INCY
$24.3B
| $4.76M | 1.1% |
42,000
+10,500
|
|
||
4
Viasat
VSAT
$11.4B
| $4.72M | 1.09% |
52,500
-21,000
|
|
||
5
Neurocrine Biosciences
NBIX
$15.6B
| $4.6M | 1.06% |
27,300
+6,300
|
|
||
6
Biogen
BIIB
$31B
| $4.54M | 1.05% |
21,000
+14,700
|
|
||
7
Hershey
HSY
$37.1B
| $4.42M | 1.02% |
25,200
+16,800
|
|
||
8
Cimpress
CMPR
$2.34B
| $4.27M | 0.98% |
42,000
+21,000
|
|
||
9
Ziff Davis
ZD
$1.89B
| $3.85M | 0.89% |
73,500
+21,000
|
|
||
10
United Natural Foods
UNFI
$2.91B
| $3.84M | 0.88% |
84,000
-21,000
|
|
||
11
Ulta Beauty
ULTA
$22B
| $3.79M | 0.87% |
8,400
+1,050
|
|
||
12
Campbell Soup
CPB
$6.92B
| $3.74M | 0.86% |
168,000
-42,000
|
|
||
13
General Mills
GIS
$21B
| $3.65M | 0.84% |
105,000
+42,000
|
|
||
14
Teradata
TDC
$2.59B
| $3.64M | 0.84% |
+105,000
|
|
||
15
Dollar General
DG
$27.3B
| $3.63M | 0.84% |
31,500
|
|
||
16
American Eagle Outfitters
AEO
$2.72B
| $3.61M | 0.83% |
210,000
|
|
||
17
PACS Group
PACS
$7.06B
| $3.58M | 0.83% |
+84,000
|
|
||
18
Aurinia Pharmaceuticals
AUPH
$2.05B
| $3.56M | 0.82% |
210,000
+126,000
|
|
||
19
Steven Madden
SHOO
$3.44B
| $3.54M | 0.81% |
84,000
|
|
||
20
Provident Financial Services
PFS
$3.22B
| $3.48M | 0.8% |
+147,000
|
|
||
21
Protolabs
PRLB
$2.17B
| $3.42M | 0.79% |
42,000
-10,500
|
|
||
22
APA Corp
APA
$14.2B
| $3.42M | 0.79% |
105,000
|
|
||
23
Newmont
NEM
$124B
| $3.42M | 0.79% |
36,600
+24,400
|
|
||
|
B
24
Barrick Mining
B
$68.6B
| $3.36M | 0.77% |
91,500
+61,000
|
|
||
25
Mercury Insurance
MCY
$5.82B
| $3.36M | 0.77% |
31,500
+10,500
|
|
Similar funds
GDS
GPP
ACG
TECP
HCM
DCM
WPW
BMC
Hussman Strategic Advisors's Q2 2026 Portfolio in Review
As of Q2 2026, Hussman Strategic Advisors held 334 positions worth $434M, down 6.2% from $463M the previous quarter. Its ten largest holdings account for 10% of the portfolio.
Hussman Strategic Advisors withdrew a net $39M in Q2 2026, closing 103 positions and reducing 42 holdings. Its most notable exit was Corcept Therapeutics, an estimated $5.08M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, up from 22% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Hussman Strategic Advisors opened a new position in Salesforce worth $3.29M.
- Hussman Strategic Advisors's largest Q2 2026 buy was Salesforce: 21,000 shares worth $3.29M.
- Hussman Strategic Advisors added most to PepsiCo in Q2 2026, an estimated $4.08M increase.
- Hussman Strategic Advisors's biggest Q2 2026 reduction was Concentrix, cutting an estimated $2.74M.
- Hussman Strategic Advisors fully exited Corcept Therapeutics in Q2 2026, selling an estimated $5.08M.
- Hussman Strategic Advisors's ten largest holdings make up 10% of its $434M portfolio in Q2 2026.
- Hussman Strategic Advisors opened 66 new positions and closed 103 in Q2 2026.
- Hussman Strategic Advisors's portfolio value fell 6.2% quarter-over-quarter to $434M.
Based on Hussman Strategic Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.